ArticleCochrane evidence synthesis and methods2023
Quick prioritization of Cochrane reviews on benign conditions of the prostate.
Article in Cochrane evidence synthesis and methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Quick prioritization of Cochrane reviews on benign conditions of the prostate.Cochrane evidence synthesis and methods · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Benign conditions of the prostate include benign prostatic enlargement and prostatitis, which constitute an important cause of morbidity in men. Objective: We aimed to generate a list of priority topics of interest to our external stakeholders within our editorial scope. Methods: Following Cochrane's guidance, we developed a tiered approach for consulting internal and external stakeholders, including members from Urological societies. First, we analyzed our portfolio, including different impact measurements, to assess the need for updates. Then, following criteria related to the feasibility, novelty and relevance of prospective topics for evidence synthesis, we narrowed the list to a suite of titles for updates or new reviews. Results: Twelve editors provided initial feedback as to what the priorities were for updating existing reviews and for new reviews in our portfolio. The editors identified gaps in our portfolio, mainly covering new treatments for benign prostatic hyperplasia. Then we consulted external stakeholders obtaining 30 responses from 14 countries. These stakeholders provided additional information about the relative importance of existing topics and suggested new ones. We identified that many of the latter were already covered in our portfolio, highlighting gaps in their dissemination. Finally, we narrowed down four priority topics that the editorial group will take forward and two additional topics that might need other considerations before being commissioned. Conclusions: Following Cochrane's guidance on priority setting, we identified topics relevant to our editors and external stakeholders by analysing our portfolio and two rounds of surveys. Moreover, we identified opportunities for disseminating existing reviews. Further evaluation is needed of the following up commissioning process for priority reviews.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.